Medtronic PLC $MDT Shares Bought by Elevation Point Wealth Partners LLC

Elevation Point Wealth Partners LLC raised its position in Medtronic PLC (NYSE:MDT) by 104.6% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 32,411 shares of the medical technology company’s stock after purchasing an additional 16,569 shares during the period. Elevation Point Wealth Partners LLC’s holdings in Medtronic were worth $3,110,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also modified their holdings of the company. Crawford Investment Counsel Inc. increased its holdings in Medtronic by 0.7% in the third quarter. Crawford Investment Counsel Inc. now owns 1,353,062 shares of the medical technology company’s stock valued at $128,866,000 after buying an additional 9,651 shares during the last quarter. CSM Advisors LLC lifted its holdings in Medtronic by 13.2% during the 3rd quarter. CSM Advisors LLC now owns 285,260 shares of the medical technology company’s stock worth $27,169,000 after buying an additional 33,167 shares during the last quarter. Ausdal Financial Partners Inc. acquired a new position in shares of Medtronic during the 3rd quarter worth about $391,000. California Public Employees Retirement System increased its holdings in shares of Medtronic by 57.9% in the 3rd quarter. California Public Employees Retirement System now owns 5,101,347 shares of the medical technology company’s stock valued at $485,852,000 after acquiring an additional 1,870,495 shares during the last quarter. Finally, Chilton Investment Co. Inc. raised its position in shares of Medtronic by 4.4% during the 3rd quarter. Chilton Investment Co. Inc. now owns 208,283 shares of the medical technology company’s stock worth $19,837,000 after acquiring an additional 8,790 shares in the last quarter. 82.06% of the stock is owned by hedge funds and other institutional investors.

Medtronic Price Performance

Medtronic stock opened at $87.05 on Friday. Medtronic PLC has a one year low of $79.55 and a one year high of $106.33. The company has a debt-to-equity ratio of 0.57, a quick ratio of 1.87 and a current ratio of 2.54. The business has a fifty day moving average of $97.96 and a two-hundred day moving average of $96.87. The company has a market cap of $111.77 billion, a P/E ratio of 24.25, a price-to-earnings-growth ratio of 2.23 and a beta of 0.71.

Medtronic (NYSE:MDT) last posted its quarterly earnings results on Tuesday, February 17th. The medical technology company reported $1.36 earnings per share for the quarter, topping analysts’ consensus estimates of $1.34 by $0.02. The business had revenue of $9.02 billion for the quarter, compared to analysts’ expectations of $8.89 billion. Medtronic had a net margin of 13.00% and a return on equity of 14.82%. The business’s revenue for the quarter was up 5.8% on a year-over-year basis. During the same period in the prior year, the company posted $1.38 EPS. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. As a group, analysts predict that Medtronic PLC will post 5.46 earnings per share for the current fiscal year.

Medtronic Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, April 17th. Shareholders of record on Friday, March 27th will be given a dividend of $0.71 per share. This represents a $2.84 annualized dividend and a yield of 3.3%. The ex-dividend date is Friday, March 27th. Medtronic’s dividend payout ratio is presently 79.11%.

Analyst Ratings Changes

Several equities analysts have commented on MDT shares. Piper Sandler reiterated a “neutral” rating on shares of Medtronic in a research note on Monday, January 5th. Leerink Partners restated an “outperform” rating and set a $119.00 price objective on shares of Medtronic in a research report on Tuesday. Morgan Stanley upped their target price on shares of Medtronic from $107.00 to $117.00 and gave the company an “overweight” rating in a report on Wednesday, November 19th. JPMorgan Chase & Co. cut their price target on shares of Medtronic from $105.00 to $100.00 and set a “neutral” rating on the stock in a research note on Wednesday, February 18th. Finally, William Blair raised shares of Medtronic from a “market perform” rating to an “outperform” rating in a research report on Tuesday, January 6th. One analyst has rated the stock with a Strong Buy rating, fifteen have given a Buy rating and ten have assigned a Hold rating to the company. According to data from MarketBeat.com, Medtronic presently has a consensus rating of “Moderate Buy” and a consensus target price of $110.74.

Insider Activity

In other news, EVP Harry Skip Kiil sold 52,524 shares of the business’s stock in a transaction that occurred on Thursday, February 19th. The stock was sold at an average price of $97.71, for a total transaction of $5,132,120.04. Following the sale, the executive vice president owned 32,768 shares of the company’s stock, valued at $3,201,761.28. The trade was a 61.58% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 0.26% of the company’s stock.

Medtronic Profile

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).